Crispr therapeutics ag (CRSP)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Collaboration revenue

289,590

3,124

40,997

5,164

247

-

Operating expenses:
Research and development

179,362

113,773

69,800

42,238

12,573

1,513

General and administrative

63,488

48,294

35,845

31,056

13,403

5,114

Total operating expenses

242,850

162,067

105,645

73,294

25,976

6,627

Loss from operations

46,740

-158,943

-64,648

-68,130

-25,729

-6,627

Other income (expense):
Interest expense

-

-

-

-8,050

-108

-

Loss from equity method investment

-5,467

-4,275

-1,763

-36,532

-

-

Gain on extinguishment of convertible loan

-

-

-

11,482

-

-

Other income (expense), net

26,033

-1,210

-197

78,512

16

-236

Total other income, net

20,566

-5,485

-1,960

45,412

-92

-236

Net loss before income taxes

67,306

-164,428

-66,608

-22,718

-25,821

-6,863

Provision for income taxes

448

553

1,749

484

7

-63

Net loss

-

-

-

-23,202

-25,828

-6,800

Net loss

66,858

-164,981

-68,357

-23,177

-25,503

-7,009

Loss attributable to noncontrolling interest

-

-

-

-25

-325

-536

Loss on extinguishment of redeemable convertible preferred shares

-

-

-

-

-

-745

Net loss

-

-

-

-23,202

-25,828

-6,800

Foreign currency translation adjustment

15

-22

40

-18

-6

-2

Comprehensive loss

66,873

-165,003

-68,317

-23,220

-25,834

-6,802

Reconciliation of net income (loss) to net income (loss) attributable to common shareholders:
Net income (loss) per share attributable to common shareholders— basic

1.23

-3.44

-1.71

-

-

-

Weighted-average common shares outstanding used in net income (loss) per share attributable to common shareholders—basic

54,392

47,964

40,057

-

-

-

Net income (loss) per share attributable to common shareholders— diluted

1.17

-3.44

-1.71

-

-

-

Weighted-average common shares outstanding used in net income (loss) per share attributable to common shareholders—diluted

56,932

47,964

40,057

-

-

-

Net loss per share attributable to common shareholders—basic and diluted

-

-

-

-1.89

-5.06

1.97

Weighted-average common shares outstanding used in net loss per share attributable to common shareholders—basic and diluted

-

-

-

12,257

5,037

3,559